Skip to main content
. Author manuscript; available in PMC: 2020 Dec 22.
Published in final edited form as: Mol Pharm. 2015 Oct 2;12(11):3986–3998. doi: 10.1021/acs.molpharmaceut.5b00432

Figure 6.

Figure 6.

Binding affinity for antigen expressing cells: (A) binding of trastuzumab ADCs to BT474 (human breast carcinoma) cells that express Her2 but not CD98; (B) binding of IGNX ADCs to murine sarcoma cells transfected with human CD98, but lacking Her2 expression.